LUSSANA, FEDERICO
LUSSANA, FEDERICO
Dipartimento di Oncologia ed Emato-Oncologia
Donor-derived CARCIK-CD19 cells engineered with Sleeping Beauty transposon in acute lymphoblastic leukemia relapsed after allogeneic transplantation
2025 F. Lussana, C.F. Magnani, S. Galimberti, G. Gritti, G. Gaipa, D. Belotti, B. Cabiati, S. Napolitano, S. Ferrari, A. Moretti, C. Buracchi, G.M. Borleri, B. Rambaldi, G. Rizzuto, A. Grassi, M. Paganessi, C. Meli, S. Tettamanti, G. Risca, G. Pais, G. Spinozzi, F. Benedicenti, G. Cazzaniga, C. Capelli, E. Gotti, M. Introna, J. Golay, E. Montini, A. Balduzzi, M.G. Valsecchi, G. Dastoli, A. Rambaldi, A. Biondi
Different Epidemiology of Invasive Pulmonary Aspergillosis in Acute Lymphoblastic Leukemia in Comparison With Acute Myeloid Leukemia: Results of a Prospective Multicentric Observational Study of the Rete Ematologica Lombarda
2025 C. Cattaneo, M. Bernardi, N. Fracchiolla, C. Pagani, F. Gigli, C. Basilico, L. Masina, E. Borlenghi, A. Bruno, G. Gela, G. Rossi, A. Tucci, D. Bertoli, F. Lussana, E. Todisco
Clinical impact of tyrosine kinases related mutations in NPM1 mutated acute myeloid leukaemia: A report from the Northern Italy Leukaemia Group (NILG) multicentre randomized trial 02/06
2025 G. Cavallaro, S. Salmoiraghi, R. Cavagna, C. Pavoni, C. Belotti, M. Milani, E. Oldani, M. Frigeni, T. Intermesoli, A. Grassi, R. Bassan, O. Spinelli, A. Rambaldi, F. Lussana
Up-front Blinatumomab Improves MRD Clearance and Outcome in Adult Ph− B-lineage ALL: the GIMEMA LAL2317 Phase 2 Study
2025 R. Bassan, S. Chiaretti, I. Della Starza, A. Santoro, O. Spinelli, M. Tosi, L. Elia, D. Cardinali, M.S. De Propris, M. Piccini, F. Lussana, M. Annunziata, P. Chiusolo, P. Zappasodi, E. Borlenghi, M. Leoncin, C. Califano, M. Bocchia, F. Di Raimondo, F. Grimaldi, M. Tiribelli, A. Candoni, A. Lico, E. Audisio, M. Lunghi, A.M. Mianulli, M. Di Trani, V. Arena, M. Messina, A. Piciocchi, P. Fazi, A. Rambaldi, R. Foà
Safety and efficacy of narsoplimab in pediatric and adult patients with transplant-associated thrombotic microangiopathy: a real-world experience
2024 M. Castelli, M.C. Micò, A. Grassi, A. Algarotti, F. Lussana, M.C. Finazzi, B. Rambaldi, C. Pavoni, G. Rizzuto, P. Tebaldi, F. Vendemini, M. Verna, S. Bonanomi, A. Biondi, A. Balduzzi, A. Rambaldi, G. Gotti
Outcome of 421 adult patients with Philadelphia-negative acute lymphoblastic leukemia treated under an intensive program inspired by the GIMEMA LAL1913 clinical trial: a Campus ALL study
2024 D. Lazzarotto, M. Cerrano, C. Papayannidis, S. Chiaretti, F. Mosna, N. Fracchiolla, P. Zappasodi, S. Imbergamo, M.I. Del Principe, M. Lunghi, F. Lussana, M. Piccini, M. Fumagalli, M. Dargenio, P. Salutari, F. Forghieri, T.G. Da Molin, M. Bonifacio, M. Olivi, F. Giglio, S. Trappolini, M. Leoncin, A. Mule, M. Delia, C. Pasciolla, F. Grimaldi, B. Cambo, L. Santoro, F. Guolo, P. Minetto, M. Defina, P. Chiusolo, M. Fanin, E. Mauro, L. Aprile, C. Mazzone, F. Trastulli, M. Ciccone, M. De Gobbi, A. Cignetti, E. De Bellis, V. Mancini, A. Piciocchi, M. Vignetti, G. Marsili, I.D. Starza, R. Fanin, M. Luppi, F. Ferrara, G. Pizzolo, R. Bassan, R. Foa, A. Candoni
Adapting the Fitness Criteria for Non-Intensive Treatments in Older Patients with Acute Myeloid Leukemia to the Use of Venetoclax-Hypomethylating Agents Combination—Practical Considerations from the Real-Life Experience of the Hematologists of the Rete Ematologica Lombarda
2024 G. Rossi, E. Borlenghi, P. Zappasodi, F. Lussana, M. Bernardi, C. Basilico, A. Molteni, I. Lotesoriere, M. Turrini, M. Frigeni, M. Fumagalli, P. Cozzi, F. Gigli, C. Cattaneo, N.S. Fracchiolla, M. Riva, G. Martini, V. Mancini, R. Cairoli, E. Todisco
Molecular prognostication for transplant decision making of patients with myelodysplastic syndromes: A retrospective single-center study
2024 A. Condorelli, M. Frigeni, G. Quaresmini, S. Salmoiraghi, C. Pavoni, A. Grassi, M. Raviglione, A. Civini, A. Putelli, F. Lussana, M.C. Finazzi, A. Algarotti, M.C. Micò, O. Spinelli, A. Rambaldi
Rituximab added to conditioning regimen significantly improves erythroid engraftment in major incompatible ABO-group hematopoietic stem cell transplantation
2024 M.C. Finazzi, A. Weber, C. Pavoni, A. Grassi, M.C. Micò, A. Algarotti, F. Lussana, A. Rambaldi
Rapid immune reconstitution following the infusion of autologous, Blinatumomab Expanded T-cells (BET) in patients with B-cell indolent NHL or CLL
2024 G. Gritti, S. Ferrari, F. Lussana, A.M. Barbui, F. Landi, M. Rondi, A. Putelli, F. Ballardini, G. Quaresmini, M. Paganessi, C. Pavoni, A. Ghirardi, E. Gotti, C. Capelli, J. Golay, M. Introna, A. Rambaldi
Optimal Use of Novel Immunotherapeutics in B-Cell Precursor ALL
2023 F. Lussana, G. Cavallaro, P. De Simone, A. Rambaldi
Autologous versus allogeneic hematopoietic cell transplantation for older patients with acute lymphoblastic leukemia. An analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
2023 S. Giebel, M. Labopin, M. Houhou, D. Caillot, J. Finke, D. Blaise, N. Fegueux, M. Ethell, J.J. Cornelissen, E. Forcade, I. Yakoub-Agha, F. Lussana, J. Maertens, J.H. Bourhis, P. Jindra, N.C. Gorin, A. Nagler, M. Mohty
Danazol Treatment for Thrombocytopenia in Myelodysplastic Syndromes: Can an "Old-fashioned" Drug be Effective?
2023 M. Riva, A. Bosi, L. Rizzo, F. Mazzon, S. Ferrari, F. Lussana, L. Borin, A. Castelli, R. Cairoli, W. Barcellini, A. Molteni, B. Fattizzo
Blinatumomab differentially modulates peripheral blood and bone marrow immune cell repertoire: A Campus ALL study
2023 D. Ocadlikova, F. Lussana, N. Fracchiolla, M. Bonifacio, L. Santoro, M. Delia, S. Chiaretti, C. Pasciolla, A. Cignetti, F. Forghieri, F. Grimaldi, G. Corradi, L. Zannoni, De , S. Propris, G.M. Borleri, I. Tanasi, J. Vadakekolathu, S. Rutella, A.R. Guarini, R. Foà, A. Curti
{COVID}-19 infection in acute lymphoblastic leukemia over 15 months of the pandemic. A Campus {ALL} report
2022 S. Chiaretti, M. Bonifacio, R. Agrippino, F. Giglio, M. Annunziata, A. Curti, M. Ilaria Del Principe, P. Salutari, M. Scium(`(e)), M. Delia, M. Armenio, V. Mancini, A. Mul(`(e)), F. Grimaldi, G. Rege-Cambrin, L. Santoro, F. Lussana, P. Chiusolo, C. Pasciolla, A. Maria Scattolin, M. Cerrano, M. Ciccone, M. Defina, F. Forghieri, C.M. Mazzone, M. Piccini, F. Ferrara, G. Pizzolo, R. Fo(`(a))
Sequential allogeneic transplantation and ruxolitinib maintenance for a synchronous PCM1-JAK2 positive myeloid sarcoma and acute B-lymphoblastic leukemia
2022 G. Rizzuto, M. Leoncin, S. Imbergamo, D. Taurino, M.C. Mico, M. Tosi, A. Michelato, K. Buklijas, O. Spinelli, F. Lussana, F. Lessi, M. Pizzi, L. Bonaldi, G. Binotto, A. Rambaldi, C. Gurrieri
Mrd‐based therapeutic decisions in genetically defined subsets of adolescents and young adult philadelphia‐negative all
2021 M. Tosi, O. Spinelli, M. Leoncin, R. Cavagna, C. Pavoni, F. Lussana, T. Intermesoli, L. Frison, G. Perali, F. Carobolante, P. Viero, C. Skert, A. Rambaldi, R. Bassan
Immunotherapy of Acute Lymphoblastic Leukemia and Lymphoma With T Cell-Redirected Bispecific Antibodies
2021 F. Lussana, G. Gritti, A. Rambaldi
Real-World Multicenter Experience in Tumor Debulking Prior to Blinatumomab Administration in Adult Patients With Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
2021 M. Bonifacio, C. Papayannidis, F. Lussana, N. Fracchiolla, M. Annunziata, S. Sica, M. Delia, R. Foà, G. Pizzolo, S. Chiaretti
Convalescent hyperimmune plasma for chemo-immunotherapy induced immunodeficiency in COVID-19 patients with hematological malignancies
2021 S. Ferrari, C. Caprioli, A. Weber, A. Rambaldi, F. Lussana